Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Blood|July 1, 1995
Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myelomaG Schiller, R Vescio, C Freytes, et al.
Cancer Research|January 27, 1998
BCL-X expression in multiple myeloma: possible indicator of chemoresistanceY Tu, S Renner, F Xu, et al.
Leukemia|August 2, 2001
Frequent demonstration of human herpesvirus 8 (HHV-8) in bone marrow biopsy samples from Turkish patients with multiple myeloma (MM)M Beksac, M Ma, C Akyerli, et al.
Bone Marrow Transplantation|March 7, 1998
Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myelomaG Schiller, R Vescio, C Freytes, et al.
Leukemia|February 23, 2012
A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myelomaJ R Berenson, O Yellin, T Kazamel, et al.
Bone Marrow Transplantation|September 15, 2015
A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCTW I Bensinger, P S Becker, T A Gooley, et al.
Leukemia|September 3, 2010
The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working GroupE Terpos, M A Dimopoulos, O Sezer, et al.
Blood|March 9, 1999
Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myelomaR Vescio, G Schiller, A K Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2000
Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung TumorsJ von Pawel, R von Roemeling, U Gatzemeier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2001
Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trialA K Stewart, R Vescio, G Schiller, et al.
Pageof 3